Category: CAR T-cell Therapy

Key Insights from Attending ASH 2025

Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC

Charting the Course of ALL: From Diagnosis to Advances

Catherine Lai, MD, MPH, University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, PA

CAR-T in 2025: Advancements and the Road Ahead

Jason Westin, M.D., MS, FACP, MD Anderson Cancer Center, Houston, TX

CAR T-cell Therapy in 2024

Michael Tees, MD, MPH, Colorado Blood Cancer Institute, Denver, CO

Highlights from attending the 2023 ASH Annual Meeting

Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY

CAR T-cell Therapy in Review 2022: Updates in Treatment

Sattva S. Neelapu, MD, M.D. Anderson Cancer Center, Houston, TX

Scroll to Top